VIA
SRPT icon

Virtus Investment Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Virtus Investment Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
75,956
+36,743
+94% +$695K 0.32% 141
2026
Q1 		$853K Buy
39,213
+7,472
+24% +$145K 0.24% 158
2025
Q4 		$683K Buy
31,741
+19,830
+166% +$418K 0.19% 181
2025
Q3 		$230K Hold
11,911
– – 0.07% 248
2025
Q2 		$204K Buy
11,911
+9,028
+313% +$385K 0.07% 237
2025
Q1 		$184K Buy
+2,883
New +$303K 0.05% 268

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Virtus Investment Advisers's SRPT Position: Q2 2026 in Review

Virtus Investment Advisers increased its Sarepta Therapeutics (SRPT) stake by 94% in Q2 2026, buying an estimated $695K and bringing the position to 75,956 shares worth $1.36M. The position accounts for 0.32% of the portfolio, ranked #141.

Virtus Investment Advisers first reported a position in SRPT in Q1 2025 and has held it in 6 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Virtus Investment Advisers held 75,956 shares of Sarepta Therapeutics worth $1.36M as of Q2 2026.
  • Virtus Investment Advisers bought 36,743 Sarepta Therapeutics shares in Q2 2026, an estimated $695K.
  • Sarepta Therapeutics made up 0.32% of Virtus Investment Advisers's portfolio in Q2 2026, its #141 holding.
  • Virtus Investment Advisers first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.